Total Versus Partial Omentectomy in the Treatment of Gastric Cancer

Launched by UNIVERSITY OF DEBRECEN · Feb 3, 2022

Keywords

ClinConnect Summary

Gastric cancer is the second common tumor type. In 2020, the incidence of gastric cancer was over one million and caused about 770 000 tumor-associated deaths worldwide. Although the improvement of the perioperative oncological therapy is unquestionable, the major point of the treatment is radical surgical intervention. Laparoscopic technic is widespread in the treatment of gastric cancer, too. For the oncological radicality total or subtotal gastrectomy with D2 omentectomy is necessary, but the opinions are divided about the role of the omentectomy. Total omentectomy in laparoscopic operat...

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • American Society of Anesthesiologists (ASA) I-III., Karnofsky Performance Score (KPS) \>60, Eastern Cooperative Oncology Group (ECOG) 0-1
• • Tis-T3 gastric cancer without serosal infiltration and treated with the radical operation (R0; D2 lymphadenectomy, lymph nodes \>16)
• • clinical stadium: Tis-3; M0
• • written informed consent provided
• • good patient compliance
• • no previous chemotherapy or irradiation
• Exclusion Criteria:
• • serosal infiltration and/or distant metastasis, omental infiltration, peritoneal carcinosis, positive abdominal cytological lavage
• • organ transplantation and/or immunological disease and/or immunomodulation therapy
• • another primary tumor
• • decompensated chronic disease (for example: liver cirrhosis with ascites, kidney failure treated with hemodialysis, New York Heart Association (NYHA) IV. cardiac status, etc.)
• • unsuccessful follow-up